tbuckley/cabot-search huggingface dataset:
KATP channels in vascular smooth muscle
Authors: J. M Quayle, N. B Standen
Journal: Cardiovascular Research (1994)

Journal Article KATP channels in vascular smooth muscle Get access John M Quayle, John M Quayle Ion Channel Group, Department of Cell Physiology and Pharmacology, University of Leicester, PO Box 138, Leicester LE1 9HN, United Kingdom: J M Quayle, N B Standen. Correspondence to Professor Standen. Search for other works by this author on: Oxford Academic PubMed Google Scholar Nicholas B Standen Nicholas B Standen Ion Channel Group, Department of Cell Physiology and Pharmacology, University of Leicester, PO Box 138, Leicester LE1 9HN, United Kingdom: J M Quayle, N B Standen. Search for other works by this author on: Oxford Academic PubMed Google Scholar Cardiovascular Research, Volume 28, Issue 6, June 1994, Pages 797–804, https://doi.org/10.1093/cvr/28.6.797 Published: 01 June 1994 Article history Received: 04 January 1994 Accepted: 21 February 1994 Published: 01 June 1994
Atmospheric chemistry of gas-phase polycyclic aromatic hydrocarbons: formation of atmospheric mutagens.
Authors: R Atkinson, J Arey
Journal: Environmental Health Perspectives (1994)

The atmospheric chemistry of the 2- to 4-ring polycyclic aromatic hydrocarbons (PAH), which exist mainly in the gas phase in the atmosphere, is discussed. The dominant loss process for the gas-phase PAH is by reaction with the hydroxyl radical, resulting in calculated lifetimes in the atmosphere of generally less than one day. The hydroxyl (OH) radical-initiated reactions and nitrate (NO3) radical-initiated reactions often lead to the formation of mutagenic nitro-PAH and other nitropolycyclic aromatic compounds, including nitrodibenzopyranones. These atmospheric reactions have a significant effect on ambient mutagenic activity, indicating that health risk assessments of combustion emissions should include atmospheric transformation products.
CONTACT DEKMATITIS I
Authors: Niels Hjorth, D. S. Wilkinson
Journal: British Journal of Dermatology (1968)

Journal Article CONTACT DEKMATITIS I Get access Niels Hjorth, Niels Hjorth Finsen Institute, Copenhagen Search for other works by this author on: Oxford Academic Google Scholar D. S. Wilkinson D. S. Wilkinson American, Buckinghamshire Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 80, Issue 1, 1 January 1968, Pages 63–65, https://doi.org/10.1111/j.1365-2133.1968.tb11909.x Published: 01 January 1968
Reply to Tomasz Drewa, Zbigniew Wolski and Janusz Tyloch's Letter to the Editor re: João Silva, Rui Pinto, Tiago Carvallho, et al. Mechanisms of Prostate Atrophy after Glandular Botulinum Neurotoxin Type A Injection: An Experimental Study in the Rat. Eur Urol 2009;56:134–41
Authors: Francisco Cruz, João Silva, Rui Pinto, Tiago Carvallho, Ana Coelho, Antonio Avelino, Paulo Dinis
Journal: European Urology (2009)
MEDICAL MEN IN THE PHILIPPINES
Authors: W. S. Osborn
Journal: JAMA (1927)

To the Editor:  —In an article entitled First-Hand Impressions of the Philippine Problem, former Secretary of War Henry L. Stimson pays the following tribute to the medical profession:  Although we in America have never heard enough about it to give it due credit, the work of the men of the Medical Corps of the United States Army and of the United States Public Health Service has written just as bright a page in the Philippines as that which in Cuba and Panama brought about the extermination of yellow fever and saved the Southern states of this country from the threat which hung over them every summer.  Among the men who contributed in a very great measure to the success of this work in the Philippines must be included the late William Everett Musgrave. I believe that some movement should be inaugurated to honor the memory of this modest, fearless, untiring
Abstract 3749: Single agent activity of PIK3CA inhibitor BYL719 in a broad cancer cell line panel
Authors: Alan Huang, Christine Fritsch, Christopher Wilson, Anupama Reddy, Manway Liu, Joseph Lehar, Cornelia Quadt, Francesco Hofmann, Robert Schlegel
Journal: Cancer Research (2012)

Abstract NVP-BYL719 is a p110α isoform-specific small molecule inhibitor that is currently in a Phase I clinical trial. To identify cancer populations that most likely to respond to BYL719 treatment, we initiated a comprehensive in vitro pharmacologic profiling screen across a large panel of cancer cell lines that have been previously characterized at the molecular level as part of the Cancer Cell Line Encyclopedia (CCLE) effort. We found that BYL719 responsive cell lines are enriched in indications such as Her2 positive and luminal breast cancer, while lacking in other indications such as Glioblastoma and Melanoma. Further exploration of the underlying genetic and pathway aberrations revealed that BYL719 sensitivity is positively associated with PIK3CA mutation, ERBB2 amplification and PIK3CA amplification/copy number gain. PTEN and BRAF mutations on the other hand, are associated with BYL719 insensitivities. KRAS mutation alone is neither associated with enhanced sensitivity nor insensitivity, however, co-commitant PIK3CA and KRAS mutants are more likely to be insensitive to BYL719 treatment. These findings will help to guide our clinical development plan. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3749. doi:1538-7445.AM2012-3749
Induction of HIV-1 Nef-specific cytotoxic T lymphocytes by Nef-expressing DNA vaccine
Authors: Yusuke Asakura, Kenji Hamajima, Jun Fukushima, Hiroshi Mohri, Takao Okubo, Kenji Okuda
Journal: American Journal of Hematology (1996)

Recently, some individuals who have remained seronegative despite definite exposure to HIV-1 have been reported. Among these individuals, an unusually high frequency of HIV-1 Nef-specific cytotoxic T lymphocytes was observed. Direct injection of plasmid DNA encoding foreign antigen can elicit both cell-mediated immunity and antibody responses (DNA vaccine). We constructed an HIV-1 Nef-expressing plasmid, and we induced HIV-1 Nef-specific cytotoxic T lymphocytes. This is the first report of inducing HIV-1 Nef-specific cytotoxic T lymphocytes by DNA vaccine.
IL-31: A new link between T cells and pruritus in atopic skin inflammation
Authors: Eniko Sonkoly, Anja Muller, Antti I. Lauerma, Andor Pivarcsi, Hortensia Soto, Lajos Kemeny, Harri Alenius, Marie-Caroline Dieu-Nosjean, Stephan Meller, Juliane Rieker, Martin Steinhoff, Thomas K. Hoffmann, Thomas Ruzicka, Albert Zlotnik, Bernhard Homey
Journal: Journal of Allergy and Clinical Immunology (2006)
Vaccination and type 1 diabetes mellitus
Authors: D. Elliman
Journal: BMJ (1999)

Papers p 1169 

The massive reduction of invasive disease due to Haemophilus influenzae type b has been an outstanding example of the value of immunisation. However, as has been the case with several vaccines, memory of the devastation caused by the disease rapidly fades and is replaced by concerns about the safety of the vaccine. These are often unfounded, but untold damage can result.1

Coincident with the increase in the number of vaccines given to children there has been a significant rise in the incidence of a number of poorly understood conditions, such as asthma, autism, and diabetes mellitus, has been noted in children in many countries.2 Of course this temporal association does not prove a causal link, and the increase in incidence often predates the introduction of most vaccines. However, the temporal associations have raised questions, and such concerns should not be dismissed out of hand.

Classen and Classen have suggested that immunisation after the age of …
Coronary stenting versus balloon angioplasty in small vessels
Authors: Raúl Moreno, Cristina Fernández, Fernando Alfonso, Rosana Hernández, Maria J. Pérez-Vizcayno, Javier Escaned, Manel Sabaté, Camino Bañuelos, Dominick J. Angiolillo, Luis Azcona, Carlos Macaya
Journal: Journal of the American College of Cardiology (2004)
HOXA9 is required for survival in human MLL-rearranged acute leukemias
Authors: Joerg Faber, Andrei V. Krivtsov, Matthew C. Stubbs, Renee Wright, Tina N. Davis, Marry van den Heuvel-Eibrink, Christian M. Zwaan, Andrew L. Kung, Scott A. Armstrong
Journal: Blood (2008)
Use of an Alternative Guidewire System in Endoscopic Placement of Biliary Endoprostheses
Authors: E. Gane, M. Lane, I. Hamilton
Journal: Endoscopy (1991)

A new guidewire with increased flexibility, torque control and a new smooth outer coating has been designed for use in interventional vascular radiology. The successful use of an adaptation of it in endoscopic management of malignant biliary strictures is reported.
The Effectiveness of Routine Screening Questions in the Detection of Alcoholism
Authors: Michele G. Cyr
Journal: JAMA (1988)

To assess the prevalence of alcoholism in an ambulatory medical clinic and to determine the effectiveness of screening questions for alcoholism, 232 new patients in a medical primary care unit were interviewed using a questionnaire that included the Michigan Alcoholism Screening Test (MAST). Based on MAST scores, 47 of 232 subjects were designated as alcoholics, yielding a prevalence of alcoholism of 20.3%. Sensitivities and specificities for alcohol-use questions were calculated using the MAST diagnosis of alcoholism. The questions "How much do you drink?" and "How often do you drink?" yielded low sensitivities of 34.0% and 46.8%, respectively. The question "Have you ever had a drinking problem?" considered alone had a high sensitivity of 70.2%; when combined with "When was your last drink?" this question had a sensitivity of 91.5%. We recommend the routine incorporation of these last two questions into the medical history in light of the high prevalence of alcoholism in this outpatient population.
Chlorpropamide-alcohol flushing and large-vessel disease in non-insulin-dependent diabetes.
Authors: A H Barnett, D A Pyke
Journal: BMJ (1980)

A total of 220 non-insulin-dependent diabetics aged over 45 (139 with a history of chlorpropamide-alcohol flushing and 81 without such a history) were examined for the prevalence of large-vessel disease. Large-vessel disease was significantly more common in the group without a history of flushing (41% v 24% of the two groups respectively; p &lt; 0.05). A history of myocardial infarction was found in 14 (17%) of the patients without flushing but in only 10 (7%) patients with flushing. Similar differences were detected in the prevalences of angina, intermittent claudication, and absent foot pulses. There were, however, no significant differences in the prevalence of cerebrovascular disease or hypertension between the two groups. These results suggest that patients with non-insulin-dependent diabetes who flush in response to chlorpropamide and alcohol are significantly less likely to develop large-vessel disease than those who do not. Hence such flushing is probably related to the pathogenesis not only of small-vessel but also of large-vessel disease.
Resistance to fulminant hepatitis and carcinogenesis conferred by overexpression of retinoblastoma protein in mouse liver
Authors: Toshiaki Ichihara, Yoshinori Komagata, Xiao-Li Yang, Tadayoshi Uezato, Katsuhiko Enomoto, Kenji Koyama, Jun-ichi Miyazaki, Toshihiro Sugiyama, Naoyuki Miura
Journal: Hepatology (2001)

Previously, retinoblastoma (Rb) transgenic mice were produced under the control of the Rb gene promoter and showed dwarf characteristics. Here, we created transgenic mice, in which the human Rb gene was controlled by the hepatocyte nuclear factor-1 gene promoter/enhancer and was expressed primarily in the liver. The liver of these novel transgenic mice was normally developed. Intriguingly, these mice showed resistance to fulminant hepatitis induced by anti-Fas antibody as well as resistance to chemical carcinogenesis in the liver. These results show that the Rb protein acts as an anti-apoptotic and anti-oncogenic agent in vivo. Our novel construct may be useful as a gene cassette in gene therapy for prevention of fulminant hepatitis and hepatoma.
882 INTERACTION BETWEEN VITAMIN D BINDING PROTEIN POLYMORPHISMS AND VITAMIN D LEVELS IN THE PREDICTION OF ANTIVIRAL RESPONSE IN CHRONIC HEPATITIS C
Authors: D. Bitetto, E. Falleti, G. Fattovich, E. Ceriani, D. Ieluzzi, M. Pasino, E. Fornsiere, S. Cmet, A. Cussigh, C. Fabris, M. Pirisi, P. Toniutto
Journal: Journal of Hepatology (2012)
IMPACT OF INTRACORONARY ADMINISTRATION OF NITROPRUSSIDE VS. NITROGLYCERINE BEFORE BALLOON DILATATION ON SLOW REFLOW DURING PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS WITH ACUTE ST ELEVATION MYOCARDIAL INFARCTION
Authors: Sudhakar Sai, L. Fischer, J. Shivkumar, J. Shivkumar, R. Vishnuarunachalam
Journal: Journal of the American College of Cardiology (2011)
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
Authors: William J. Sandborn, Brian G. Feagan, Paul Rutgeerts, Stephen Hanauer, Jean-Frédéric Colombel, Bruce E. Sands, Milan Lukas, Richard N. Fedorak, Scott Lee, Brian Bressler, Irving Fox, Maria Rosario, Serap Sankoh, Jing Xu, Kristin Stephens, Catherine Milch, Asit Parikh
Journal: New England Journal of Medicine (2013)

The efficacy of vedolizumab, an α4β7 integrin antibody, in Crohn's disease is unknown.In an integrated study with separate induction and maintenance trials, we assessed intravenous vedolizumab therapy (300 mg) in adults with active Crohn's disease. In the induction trial, 368 patients were randomly assigned to receive vedolizumab or placebo at weeks 0 and 2 (cohort 1), and 747 patients received open-label vedolizumab at weeks 0 and 2 (cohort 2); disease status was assessed at week 6. In the maintenance trial, 461 patients who had had a response to vedolizumab were randomly assigned to receive placebo or vedolizumab every 8 or 4 weeks until week 52.At week 6, a total of 14.5% of the patients in cohort 1 who received vedolizumab and 6.8% who received placebo were in clinical remission (i.e., had a score on the Crohn's Disease Activity Index [CDAI] of ≤150, with scores ranging from 0 to approximately 600 and higher scores indicating greater disease activity) (P=0.02); a total of 31.4% and 25.7% of the patients, respectively, had a CDAI-100 response (≥100-point decrease in the CDAI score) (P=0.23). Among patients in cohorts 1 and 2 who had a response to induction therapy, 39.0% and 36.4% of those assigned to vedolizumab every 8 weeks and every 4 weeks, respectively, were in clinical remission at week 52, as compared with 21.6% assigned to placebo (P<0.001 and P=0.004 for the two vedolizumab groups, respectively, vs. placebo). Antibodies against vedolizumab developed in 4.0% of the patients. Nasopharyngitis occurred more frequently, and headache and abdominal pain less frequently, in patients receiving vedolizumab than in patients receiving placebo. Vedolizumab, as compared with placebo, was associated with a higher rate of serious adverse events (24.4% vs. 15.3%), infections (44.1% vs. 40.2%), and serious infections (5.5% vs. 3.0%).Vedolizumab-treated patients with active Crohn's disease were more likely than patients receiving placebo to have a remission, but not a CDAI-100 response, at week 6; patients with a response to induction therapy who continued to receive vedolizumab (rather than switching to placebo) were more likely to be in remission at week 52. Adverse events were more common with vedolizumab. (Funded by Millennium Pharmaceuticals; GEMINI 2 ClinicalTrials.gov number, NCT00783692.).
Distribution of lymphoid neoplasms in the Republic of Korea: Analysis of 5318 cases according to the World Health Organization classification
Authors: Sun Och Yoon, Cheolwon Suh, Dae Ho Lee, Hyun‐Sook Chi, Chan Jeoung Park, Seong‐Soo Jang, Hai‐Rim Shin, Bong‐Hee Park, Jooryung Huh
Journal: American Journal of Hematology (2010)

Abstract Compared with the West, the overall incidence of lymphoid neoplasms is lower, and the subtype distribution is distinct in Asia. To comprehensively investigate the subtype distribution with the age and sex factors, and temporal changes of subtype proportions, we re‐assessed all patients with lymphoid neoplasms diagnosed at a large oncology service in the Republic of Korea from 1989 to 2008 using the World Health Organization classifications. Of the total 5,318 patients, 66.9% had mature B‐cell neoplasms, 12.5% had mature T/natural killer (NK)‐cell neoplasms, 16.4% had precursor lymphoblastic leukemia/lymphoma (ALL/LBL), and 4.1% had Hodgkin's lymphoma. The most common subtypes were diffuse large B‐cell lymphoma (30.5%), plasma cell myeloma (14.0%), extranodal marginal zone lymphoma of mucosa‐associated lymphoid tissue type (MALT lymphoma; 12.4%), B‐cell ALL/LBL (11.3%), Hodgkin's lymphoma (4.1%), peripheral T‐cell lymphoma unspecified (4.0%), T‐cell ALL/LBL (3.9%), and extranodal NK/T‐cell lymphoma of nasal type (3.9%). Most subtypes showed male predominance, with an average M/F ratio of 1.3. Most mature lymphoid neoplasms were diseases of adults (mean age, 53.5 yr), whereas ALL/LBLs were of young individuals (mean age, 20.3 yr). When the relative proportion of subtypes were compared between two decades (1989–1998 vs. 1999–2008), especially MALT lymphoma has increased in proportion, whereas T/NK‐cell neoplasms and ALL/LBL have slightly decreased. In summary, the lymphoid neoplasms of Koreans shared some epidemiologic features similar to those of other countries, whereas some subtypes showed distinct features. Although the increase in incidence of lymphoid neoplasms is relatively modest in Korea, recent increase of MALT lymphoma and decrease of T/NK‐cell neoplasms and ALL/LBL are interesting findings. Am. J. Hematol., 2010. © 2010 Wiley‐Liss, Inc.
US needs 52 000 more primary care doctors by 2025, new study says
Authors: J. H. Tanne
Journal: BMJ (2012)

The United States will need nearly 52 000 more primary care doctors by 2025, estimates a new study that looked at numbers of patients’ visits to their doctors. 

Population growth will be the largest factor driving the need for more primary care doctors, accounting for about 33 000 more, says the study, published in the Annals of Family Medicine .1

An additional 10 000 primary care doctors would be needed to care for the aging population and about 8000 more for the roughly 34 million people newly insured as a result of the Affordable Care …
BMS-911543 inhibits viability of tumor and stromal cells and limits disease progression in genetically engineered mice with pancreatic cancer
Authors: Thomas Mace, Reena Shakya, Benjamin Swanson, Thomas Ludwig, Omar Elnaggar, Hannah Komar, Jennifer Yang, Gregory Young, Wendy Frankel, Peter Muscarella, Tanios Bekaii-Saab, Mark Bloomston, Gregory Lesinski
Journal: Journal for ImmunoTherapy of Cancer (2014)

Meeting abstracts Pancreatic cancer (PCa) is resistant to cytotoxic therapies, and the profound immune suppressive nature of this disease renders patients non-responsive to immunologic therapies. Signaling downstream of IL-6 is important in the genesis and progression of PCa. The IL-6/Jak2/STAT3
Will intermediate care be the undoing of the NHS?
Authors: A. M Pollock
Journal: BMJ (2000)

The government has won praise for its new plan for the NHS,1 where it reaffirms its commitment to the principles of a universal comprehensive health service. Yet for the first time in its history NHS bodies will be able to levy charges for the personal elements of care. The commitment to services free at the point of delivery is absent from the NHS plan.

Following the National Beds Inquiry2 the government has announced the creation of 7000 extra NHS beds by 2004, 5000 of which will be intermediate care beds and 1700 non-residential places. Intermediate care will “build a bridge between hospital and home” to speed discharge from acute care and provide a range of recovery and rehabilitation services. Cottage hospitals, private nursing homes, and domiciliary and community settings will form the heart of the new intermediate sector. What has received less attention is how these services will be funded.

In the plan the government also published its response to the Royal Commission on Long Term Care.3 From October 2001 the NHS is committed to meet the costs only of nursing care for nursing home residents; personal care will be charged for. This means that in future nursing care will be free for all of the 160 000 nursing home residents in England who …
935 OVEREXPRESSION OF CREM ALPHA IN CD4+ T CELLS ACCELERATES ACUTE ConA-INDUCED HEPATITIS BUT DOES NOT INFLUENCE FIBROSIS
Authors: L. Hammerich, C. Schönherr, M. Stefkova, K. Ohl, T. Lüdde, C. Trautwein, K. Tenbrock, F. Tacke
Journal: Journal of Hepatology (2013)
INFECTION AND INTOXICATION
Authors: F. S. Robscheit-Robbins, G. H. Whipple
Journal: The Journal of Experimental Medicine (1936)

Infection in human cases is often believed to be responsible for anemia. It is generally believed that lack of absorption and definite blood destruction are responsible for the anemia. Accelerated metabolism due to thyroid or dinitrophenol does not modify hemoglobin production in these standard anemic dogs. Endometritis lasting over many weeks will profoundly reduce the production of hemoglobin in the standard anemic dog. A sterile abscessalso will diminish the production of new hemoglobin in the anemic dog when liver is being fed but particularly during fasting periods when the usual abundant production of new hemoglobin is reduced to zero. Impaired absorption can be excluded as a factor of any significance in certain experiments given above. Destruction of red cells can likewise be excluded as of any significance in certain experiments given above. These experiments point to a disturbance of internal metabolism related to hemoglobin building in the body as responsible for the inhibition of hemoglobin production under these conditions. We believe this same factor is often of importance in human disease.
Saddle Embolus of the Aorta
Authors: Irwin J. Schatz, James C. Stanley
Journal: JAMA (1976)

ACUTE embolic occlusion of the terminal aorta at its bifurcation is a common and life-threatening cardiovascular catastrophe. Aortic saddle embolus accounts for approximately 10% of all peripheral arterial emboli. It is invariably a reflection of severe, coexisting heart disease.  Physicians must be sufficiently familiar with the characteristic clinical manifestations of saddle embolus in order to reach the diagnosis promptly, recommend appropriate therapy, and avoid irreversible ischemic injury. Time is of the essence in the successful treatment of patients with this disease.  Pathogenesis  Sudden embolic occlusion of the terminal aorta is almost always caused by dislodged intracardiac mural thrombi, from either the left ventricle or left atrium. Perhaps the most common source of large emboli is the left ventricular chamber in patients who have had a recent myocardial infarction. Endocardial inflammation and roughening becomes the site for mural thrombosis. During early convalescence from infarction, such thrombi may become detached from the